Retrophin Announces Agreement to Acquire Manchester Pharmaceuticals

13-02-2014 Business Wire HealthComments (0)


Retrophin (NASDAQ: RTRX) today announced that it has signed an agreement to acquire Manchester Pharmaceuticals LLC, a privately-held specialty pharmaceutical company that focuses on treatments for rare diseases. Under the terms of the agreement, Retrophin will pay a total of $62.5 million, including an upfront payment of $29.5 million, plus royalties based on product sales. The transaction is expected to close by March 1, 2014. Manchester markets two drugs that

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top